Refined 1.2 A crystal structure of the complex formed between subtilisin Carlsberg and the inhibitor eglin c. Molecular structure of eglin and its detailed interaction with subtilisin - PubMed (original) (raw)

Refined 1.2 A crystal structure of the complex formed between subtilisin Carlsberg and the inhibitor eglin c. Molecular structure of eglin and its detailed interaction with subtilisin

W Bode et al. EMBO J. 1986 Apr.

Abstract

The crystal structure of the complex formed between eglin c, an elastase inhibitor from the medical leech, and subtilisin Carlsberg has been determined at 1.2 A resolution by a combination of Patterson search methods and isomorphous replacement techniques. The structure has been refined to a crystallographic R-value of 0.18 (8-1.2 A). Eglin consists of a four-stranded beta-sheet with an alpha-helical segment and the protease-binding loop fixed on opposite sides. This loop, which contains the reactive site Leu45I--Asp46I, is mainly held in its conformation by unique electrostatic/hydrogen bond interactions of Thr44I and Asp46I with the side chains of Arg53I and Arg51I which protrude from the hydrophobic core of the molecule. The conformation around the reactive site is similar to that found in other proteinase inhibitors. The nine residues of the binding loop Gly40I--Arg48I are involved in direct contacts with subtilisin. In this interaction, eglin segment Pro42I--Thr44I forms a three-stranded anti-parallel beta-sheet with subtilisin segments Gly100--Gly102 and Ser125--Gly127. The reactive site peptide bond of eglin is intact, and Ser221 OG of the enzyme is 2.81 A apart from the carbonyl carbon.

PubMed Disclaimer

Cited by

The murine Spi-2 proteinase inhibitor locus: a multigene family with a hypervariable reactive site domain.
Inglis JD, Hill RE. Inglis JD, et al. EMBO J. 1991 Feb;10(2):255-61. doi: 10.1002/j.1460-2075.1991.tb07945.x. EMBO J. 1991. PMID: 1991447 Free PMC article.
X-ray crystal structure of the complex of human leukocyte elastase (PMN elastase) and the third domain of the turkey ovomucoid inhibitor.
Bode W, Wei AZ, Huber R, Meyer E, Travis J, Neumann S. Bode W, et al. EMBO J. 1986 Oct;5(10):2453-8. doi: 10.1002/j.1460-2075.1986.tb04521.x. EMBO J. 1986. PMID: 3640709 Free PMC article.
Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8.
Stennicke HR, Renatus M, Meldal M, Salvesen GS. Stennicke HR, et al. Biochem J. 2000 Sep 1;350 Pt 2(Pt 2):563-8. Biochem J. 2000. PMID: 10947972 Free PMC article.
Structure of a switchable subtilisin complexed with a substrate and with the activator azide.
Gallagher T, Ruan B, London M, Bryan MA, Bryan PN. Gallagher T, et al. Biochemistry. 2009 Nov 3;48(43):10389-94. doi: 10.1021/bi900577n. Biochemistry. 2009. PMID: 19761257 Free PMC article.
The solution structure of eglin c based on measurements of many NOEs and coupling constants and its comparison with X-ray structures.
Hyberts SG, Goldberg MS, Havel TF, Wagner G. Hyberts SG, et al. Protein Sci. 1992 Jun;1(6):736-51. doi: 10.1002/pro.5560010606. Protein Sci. 1992. PMID: 1304915 Free PMC article.

References

1. Hoppe Seylers Z Physiol Chem. 1977 Sep;358(9):1105-7 - PubMed
1. J Mol Biol. 1977 May 25;112(3):535-42 - PubMed
1. Hoppe Seylers Z Physiol Chem. 1980 Dec;361(12):1841-6 - PubMed
1. Adv Protein Chem. 1981;34:167-339 - PubMed
1. Science. 1982 Apr 30;216(4545):539-40 - PubMed

Refined 1.2 A crystal structure of the complex formed between subtilisin Carlsberg and the inhibitor eglin c. Molecular structure of eglin and its detailed interaction with subtilisin - PubMed (original) (raw)